Highest-materiality recent filing
Lineage Cell Therapeutics Q2 2026 net income $1.5M; cash runway to Q3 2028
Q2 2026 net income of $1.5M ($0.01 basic EPS) vs net loss of $30.5M in Q2 2025; revenue $1.1M, down from $2.8M.
Lineage Q1 2026 net loss $4.8M; cash $53.4M; new COR1 program launched
Net loss $4.8M ($0.02 basic/$0.03 diluted EPS) vs $4.1M loss in Q1 2025.
Lineage Q4 net income $0.9M, full-year loss $63.5M; cash runway into Q2 2028
Q4 2025 revenue $6.6M (up from $2.9M YoY); net income $0.9M ($0.004 EPS) vs net loss $3.3M ($0.02 loss) in Q4 2024.
Lineage achieves first OpRegen milestone under Roche deal; $5M payment triggered
First development milestone under Roche Agreement for OpRegen (RG6501) achieved; $5M payment triggered.
Lineage Cell Therapeutics sells 12M shares at $1.75 to Janus Henderson, grossing $21M
Sold 12,000,000 common shares at $1.75 per share to Janus Henderson Investors in a block transaction.
Lineage Q3 net loss widens to $29.8M on warrant remeasurement; cash $40.5M
Net loss $29.8M ($0.13/sh) vs $3.0M ($0.02) in Q3 2024; includes $26.6M non-cash warrant remeasurement.
Lineage Cell Therapeutics enters collaboration with WDI for hearing loss program; up to $12M funding
Multi-year research collaboration with William Demant Invest 2 Aps to advance ReSonance (ANPI) preclinical program for hearing loss.
Q2 2025 revenue $2.8M (+$1.4M YoY); net loss $30.5M ($0.13/sh) vs $5.8M ($0.03) YoY.
Lineage reports OpRegen 36-month data: +9 ETDRS letters in extensive-coverage GA patients
Mean BCVA gain of +6.2 letters (n=10) persisting through 36 months vs. +5.5 at 24 months.
Lineage Cell narrows Q4 net loss to $3.3M; OpRegen gets FDA RMAT designation
Net loss of $3.3M ($0.02/shr) for Q4 2024 vs $4.8M ($0.03/shr) in Q4 2023; revenue $2.9M vs $2.1M.
Lineage closes $6M second tranche of registered direct offering; total $30M received
Second tranche closed Jan 27, 2025; issued 7,894,737 common shares + warrants at $0.76/unit.
Lineage Cell Therapeutics prices $30M registered direct offering at $0.76/unit with warrants
Combined purchase price of $0.76 per share and warrant; $24M from institutional investors, $6M from Broadwood affiliate.
Lineage Cell Therapeutics Q3 2024 net loss $3.0M, revenue $3.8M; OpRegen gets RMAT designation
Net loss $3.0M ($0.02/sh) vs $7.1M ($0.04/sh) in Q3 2023; revenue $3.8M vs $1.2M.
Lineage Cell Therapeutics Q2 net loss $5.8M as revenue falls 56% to $1.4M
Net loss attributable to Lineage $5.8M ($0.03/share) vs $5.2M prior year; revenue $1.4M vs $3.2M.
Lineage Cell Therapeutics files $40M ATM equity offering via B. Riley
Prospectus supplement filed May 14, 2024 to sell up to $39,966,424 of common shares at-the-market.
Lineage Cell Therapeutics Q1 2024: rev $1.4M, net loss $6.5M; new Genentech OpRegen deal
Revenue of $1.4M, down from $2.4M YoY; net loss attributable $6.5M ($0.04/sh) vs $4.4M ($0.03/sh).
Lineage Cell Therapeutics enters new ATM facility with B. Riley; FDA delays OPC1 study start
Entered Sales Agreement with B. Riley Securities to sell up to $6.7M in common shares via at-the-market offering; 3% commission.
Lineage Cell Therapeutics reports FY2023 net loss $21.5M; cash runway into Q3 2025
FY2023 revenue $8.9M, down 39% from $14.7M in 2022; net loss $21.5M ($0.12/sh).
Lineage Cell Therapeutics enters $14M registered direct offering at $1.04/share
Sale of 13,461,540 common shares at $1.04 each; gross proceeds of $14.0M.
Lineage Q2 net loss narrows to $5.2M; OpRegen phase 2a enrolling, OPC1 IND plan in Q4
Net loss narrowed to $5.2M ($0.03/shr) from $6.8M ($0.04/shr) in Q2 2022.
Lineage Cell Therapeutics Q1 net loss $4.4M, cash $46.8M; OpRegen phase 2a enrolling
Revenue $2.4M, down 54% YoY from $5.2M due to lower Roche collaboration revenue.
Lineage Cell Therapeutics Q4 net loss $6.4M, revenue $1.9M; cash $57.9M; pipeline advances
Q4 2022 net loss $6.4M ($0.03/sh), revenue $1.9M; FY2022 net loss $26.3M ($0.15/sh), revenue $14.7M.
Lineage Cell Therapeutics settles Asterias merger lawsuit for $10.65M
Settlement of $10.65M funded ~$7.12M by insurers and ~$3.53M by Lineage (cash or shares).
Lineage reports Q2 net loss of $6.8M ($0.04/sh); cash $72M supports through Q2 2024
Revenue $4.6M, up $4.0M YoY, primarily from Roche collaboration licensing fee.
CFO Kevin L. Cook resigns; CEO Brian M. Culley named interim CFO effective July 8, 2022
CFO Kevin L. Cook resigns effective July 8, 2022; resignation not due to any disagreement with Lineage.
Lineage Cell reports OpRegen Phase 1/2a data: 7.6-letter visual gain in Cohort 4 at 12 months
24 patients treated; no cases of rejection or intraocular inflammation reported.
Lineage Q1 net loss $7.1M ($0.04/sh); cash $78.1M; pipeline expanded
Net loss attributable to Lineage of $7.1M ($0.04/sh) vs $1.4M ($0.01/sh) in Q1 2021.
Lineage Cell reports Q4 net loss $0.17/sh; cash $55.7M; Roche deal up to $670M
Q4 2021 net loss $29.0M ($0.17/sh) vs net income $2.0M ($0.01/sh) in Q4 2020; FY 2021 net loss $43.0M ($0.26/sh).
Lineage Cell Therapeutics grants 694,424 RSUs tied to Roche collaboration milestones
RSUs awarded to employees and executive officers; half vest over 4 years, half upon milestone achievement under Roche License Agreement.
Lineage Cell Therapeutics launches new $64.1M at-the-market equity offering
Prior $25M ATM program terminated; $14.1M remained unsold.
On October 28, 2022, Lineage Cell Therapeutics, Inc. (“Lineage,” “we,” “us,” “our,” or the “Company”) appointed Jill A. Howe as its Chief Financial Officer, effective November 14, 2022.
Max materiality 0.70 · Median 0.60 · Most common event other_material